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Background: Although the studies published so far have found an affectation in the Health Related Quality of Life
(HRQOL) in both psychiatric and substance use dependence disorders, very few studies have applied HRQOL as an
assessment measure in patients suffering both comorbid conditions, or Dual Diagnosis. The aim of the current
study was to assess HRQOL in a group of patients with Dual Diagnosis compared to two other non-comorbid
groups and to determine what clinical factors are related to HRQOL.
Methods: Cross-sectional assessment of three experimental groups was made through the Short Form – 36 Item
Health Survey (SF-36). The sample consisted of a group with Dual Diagnosis (DD; N = 35), one with Severe Mental
Illness alone (SMI; N = 35) and another one with Substance Use Dependence alone (SUD; N = 35). The sample was
composed only by males. To assess the clinical correlates of SF-36 HRQOL, lineal regression analyses were carried
out.
Results: The DD group showed lower scores in most of the subscales, and in the mental health domain. The group
with SUD showed in general a better state in the HRQOL while the group with SMI held an intermediate position
with respect to the other two groups. Daily medication, suicidal attempts and daily number of coffees were
significantly associated to HRQOL, especially in the DD group.
Conclusions: The DD group showed lower self-reported mental health quality of life. Assessment of HRQOL in dual
patients allows to identify specific needs in this population, and may help to establish therapeutic goals to improve
interventions.
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In the last two decades there has been an increasing inter-
est in Quality of Life (QOL) and Health related Quality of
life (HRQOL) as an assessment measure in care interven-
tions, adverse effects of treatment and the impact of the
illness through time [1], especially in psychiatric popula-
tion [2]. Different studies have found an affectation both
in the QOL and in the HRQOL in psychiatric disorders
such as schizophrenia and bipolar disorder [3-7], as well
as in substance dependence disorders [8-10].
Assessment of both QOL and HRQOL in Dual Diagnosis
(DD) patients may help to identify areas of specific and* Correspondence: aadan@ub.edu
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reproduction in any medium, provided the orclinical attention, given the special characteristics of this
population: faster relapses [11], higher rates of rehospitali-
zation and imprisonment [12], lower participation in the
health services, more loss of social support and financial
problems [12-14]. All these factors may be indicative of a
lesser QOL in patients with DD, and its detection and clin-
ical assistance could improve the efficacy of the interven-
tions. Both QOL and HRQOL may represent useful
measurements to assess the efficacy of such interventions.
Although there are few studies on the QOL in DD,
most of the data published up to now show a worse
QOL in these patients. Singh et al. [15] obtained a worse
general QOL in DD patients with bipolar disorder com-
pared with bipolar patients without comorbid Substance
Use Dependence (SUD), with patients with SUD alone
and with a normal control group. Kilbourne et al. [16]
found that illicit drug use was associated with a decreasedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effect continued one year later, even after controlling for
the maniac and depressive symptoms of the disorder.
Kalman et al. [17] obtained a lower mental HRQOL in a
sample of dual patients with heterogeneous psychiatric dis-
orders, compared with subjects with Severe Mental Illness
(SMI) alone and with alcohol dependence alone. Bizarri
et al. [18] also found a worse score in all the assessed
domains of QOL in DD patients with opium dependence
compared to patients without a concomitant mental dis-
order, and the differences were more marked in the
domains of mental and physical functioning. In the study
by Fassino et al. [19], the heroin dependent patients with
comorbid personality disorder presented a worse QOL than
those heroin dependent without the comorbidity.
However, some works do not obtain such differences,
as for example in Astals et al. [20], which assessed the
HRQOL in patients with and without a concomitant
psychiatric disorder under treatment for heroin depend-
ence. In the study by Garg et al. [21], the DD had worse
scores in the dimension of Vitality but not in mental
and physical health domains. Finally, Wade et al. [22], in
a sample of young patients with a first psychotic episode,
observed that the affectation in both QOL and social
functioning were related to the level of severity in sub-
stance use. Thus, the QOL in patients with mild con-
sumption did not differ from that of non-consumers,
while it was worse in patients with heavy consumption.
The variety of definitions on QOL, sample characteris-
tics, design of the studies and different instruments and
procedures applied can be explanatory factors of the het-
erogeneity of results.
The aim of our study was to assess HRQOL through
SF–36 in a group of patients with DD, and compare it to
the group with SMI and to the third group with SUD as
well as to establish comparisons to published values for
the normal Spanish population according to the mean
age of our sample and male gender norms [23]. To our
knowledge, no other previous research has worked with
this design, including these three experimental groups
and their comparisons to normative data. We expected
higher scoring in the SUD group, indicative of a better
HRQOL state, while the SMI group would be in the
medium scoring range and DD would present the worse
HRQOL scores, especially in the mental health domain.
In an exploratory way, we further sought to determine
which clinical factors would be related to HRQOL, with
special interest in the DD group.
Material and methods
Sample and procedure
This study is part of a larger study on health related
quality of life, neurocognitive functioning and personal-
ity traits in patients with DD. In the present paper, weonly present the data concerning health-related quality
of life.
In a prospective cross-sectional design we enrolled
125 male patients aged 18 to 60 years, divided in three
groups. Two groups with a severe mental illness (schizo-
phrenia, bipolar disorder, or major depressive disorder)
with comorbid SUD (DD) and without comorbid SUD
(SMI), and they were consecutively admitted to “social
club program” at the Mental Health Division of the
Althaia Foundation in Manresa (Barcelona, Spain). A
third group of patients with SUD without psychiatric
comorbidity (SUD) was under treatment on the thera-
peutic community of the Gressol Catalonia Man Project
(Barcelona), between January 2010 and June 2011. Each
participant was consecutively referred by their treating
psychiatrist, who was blind to the aims of the study, and
had been diagnosed using the Structural Clinical Inter-
view for DSM-IV-R [24] Axis I Disorders (SCID-I) [25].
The inclusion criteria were: (1) Current diagnosis of
schizophrenia, bipolar disorder or major depression; or
current diagnosis of substance use dependence in remis-
sion for at least four months and absence of relapses at
least one month before the study participation; (2) male
gender; (3) age between 18–60 years. The SUD group has
the additional criterion of no other current DSM-IV-R cri-
teria for any Axis I or II disorders. The exclusion criteria
were: no DSM-IV-R criteria for a current substance-
induced psychiatric disorder or psychiatric disorder due to
a medical condition, unstable or severe medical illness,
mental retardation, history of traumatic brain injury or
neurological injury, violent behavior and having received
electroconvulsive therapy within 12 months prior to their
study participation.
The procedure of the study was divided into 4 one hour
long sessions. The data presented in this study was col-
lected in the first session by a doctoral level psychologist,
and written informed consent was obtained from all parti-
cipants after the procedures of the study were fully
explained to them. In the following sessions we carried
out neurocognitive and personality assessments. A urine
drug screen was performed between the first and the sec-
ond session of the study. After this initial assessment and
during the course of the study, 20 patients were excluded.
The analyses were performed with a total sample of 105,
divided into 35 subjects in each group (see Figure 1).
This study was approved by the ethics committees of
the University of Barcelona and the Mental Health
Division of Althaia, meeting the ethical principles of the
Declaration of Helsinki.
Instruments
Clinical measures
Information was collected by means of a structured
interview of sociodemographic (age, marital status, social
Patients with Psychiatric Disorder with and 
without SUD
“Social Club Program” at the Mental Division 
of Althaia Foundation in Manresa (Barcelona).  
Total N=85
SMI group (n=41)    DD group (n=44) 
Patients with SUD without  psychiatric 
Disorder 
“Therapeutic Community” of the Gressol 
Catalonia Man Project (Barcelona) 
SUD group N = 40 
   N= 125 enrolled in the study                  
SMI group: N = 6 Excluded 
n= 1: Psychiatric disorder due to a medical 
condition
n=5:  Dropped out the study.   
DD group: N= 9 Excluded 
n= 4: Positive urinalysis 
n= 1: Violent behavior 
n= 1: Relapse during the course of the study
n=2: Dropped out the study 
N= 15 Excluded N= 5 Excluded 
n= 2 Met criteria for DSM-IV Axis 
II disorders
n= 3 Dropped out the study  
SUD group: N= 35 
DD group: N= 35 SMI group: N= 35 
Figure 1 Participants flow-chart. DD, Dual Diagnosis; SMI, Severe Mental Illness; SUD, Substance Use Dependence.
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ables (diagnosis, psychiatric and substance use family
history, age of onset of the disorder and/or consump-
tion, relapses, abstinence periods, type of drug used, sui-
cidal attempts, presence of organic pathology and
medication). We reviewed the medical records of the
patients, contrasting the self-reported data with the
medical history on the database of the hospital and with
their treating psychiatrist. Daily consumption of cigar-
ettes and cups of coffee as well as other intakes of bever-
age with caffeine, such as tea or cola, were recorded.
Smokers were administered the Fagerström test [26] of
nicotine dependence. Additionally, the Clinical Global
Impression [27] was applied as a subjective measure of
the clinical severity of each participant.
Health- related quality of life
To assess the HRQOL we selected the SF-36 question-
naire [28] (Short Form −36 Item Health Survey), one of
the most used and adequate generic instruments in psy-
chiatric [29,30] and drug addicted population [31]. TheSpanish version has good psychometric properties and
reference population values [23]. The SF-36 provides
scores in 8 dimensions: Physical Functioning, Role -
Physical, Role - Emotional, Social Functioning, Mental
Health, General Health, Bodily Pain, and Vitality, with
scores ranging from 0 to 100, where a higher score indi-
cates a better functioning in the scale. It also has an add-
itional item measuring the Health Changes perceived by
the subject in comparison to the previous year (Health
Transition item). The questionnaire provides two com-
posite standardized scales in T scores with mean 50 and
standard deviation 10: the Physical health Component
Summary (PCS) and the Mental health Component
Summary (MCS). These two scales explain 80 to 85% of
the variance in the 8 original dimensions and have
shown greater reliability [32].
Statistical analysis
We calculated the descriptive statistics for all the vari-
ables. The possible intergroup differences (DD, SMI and
SUD) in the sociodemographic and clinical variables
Table 1 Sociodemographic data for the three groups of
patients
Sociodemographics DD (N=35) SMI (N = 35) SUD (N=35)
Age 37.91 ± 8.34 yr 38.63 ± 8.73 yr 36.37 ± 6.72 yr
Marital status
Single 60.0% 85.7% 51.4%
Stable partner 11.4% 0% 8.6%
Married 2.9% 5.7% 11.4%
Separate/Divorced 11.5% 8.6% 28.5%
Widower 2.9%
Number of children 0.49 ± 1.09 0.17 ± 0.51 0.51 ± 0.78
Living
Alone 20.0% 8.6% 2.9%
Accompanied 77.1% 91.4% 88.6%
Years of study 9.14 ± 2.01 9.66 ± 2.44 9.58 ± 2.23
Economic situation
Active 8.6% 14.3% 42.9%
Disability pension 65.7% 74.3% 17.1%
Unemployed 11.4% 20.0%
No income 8.6% 11.4% 20.0%
DD, Dual Diagnosis; SMI, Severe Mental Illness; SUD, Substance Use
Dependence.
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ate analyses (MANOVA) for the continuous data. Cat-
egorical data were examined with Chi Square tests in the
case of variables with nominal scales (marital status,
economic situation, living situation, type of medical
comorbidities, and type of psychotropic medication, psy-
chiatric diagnosis, type of intake of substance/depend-
ence and degree of dependency on the Fagerström tests).
The intergroup differences in the HRQOL were exam-
ined by MANOVAs and later introduced covariates in
analysis (MANCOVA) to explore the variance of its effect
on the HRQOL. In all cases, we estimated the power sam-
ple so that the statistical test would not reject the null
hypothesis wrongly by not detecting an effect if there were
one. We considered values from 0.70 as suitable. The stat-
istic partial squared Eta (ηp
2) was also estimated to meas-
ure the effect size, that is, the degree to which each factor
is affecting the dependent variable, where a value of 0.01
was low, 0.04 moderate and 0.1 high [33]. Both statistics
are used to avoid the occurrence of type II error. All ana-
lyses were Bonferroni corrected due to the multiple com-
parisons carried out in order to control the possibility that
the statistical tests would find an effect where there was
not one. Thus, this correction method prevents from the
occurrence of Type I error.
Finally, in an exploratory way, we carried out a bivari-
ate correlational analysis between the demographic and
clinical variables with the summatory scores of the PCS
and the MCS. We intended to identify the variables of
interest to be introduced in the following lineal regres-
sion analysis, trying to find clinical correlates of the
HRQOL. The analyses were done with the statistical
package SPSS (version 15.0) and the tests were consid-
ered bilaterally with a type I error established at 5%.
Results
Sociodemographic and clinical variables
Table 1 and Table 2 summarize the sociodemographic
and clinical data of the sample. Groups were equivalent
in age, number of children, years of schooling and type
of cohabitation. There were intergroup differences in
marital status (χ2 = 9.891; p = 0.007), with a higher per-
centage of singles in the SMI than in both DD and SUD
groups, and in the economic status (χ2 = 26.651;
p < 0.0001), with a higher percentage of subjects receiv-
ing a disability pension in both DD and SMI groups
compared to a higher percentage of active workers in
SUD group (See Table 1).
With respect to the clinical variables (Table 2), we
obtained main effects in number of daily medications
(F(2,102) = 47.162; p = 0.0001; ηp
2 = 0.048). The DD group
was taking more daily medications than the SMI
group (p = 0.016) and the latter more than the SUD
group (p= 0.0001). Considering the type of psychotropicmedication, both DD and SMI groups were taking more
typical and atypical antipsychotics, mood stabilizers,
anxiolytics and than the SUD group (χ2 ≥ 8.864;
p ≥ 0.012).
The DD group also had more suicidal attempts
(F(2,102) = 4.630; p = 0.010; ηp
2 = 0.083) than the SMI and
SUD (p = 0.010) groups, without difference between the
latter two groups.
A higher score in the Fagerström test was found in
the DD and SUD groups (F (2,102) = 5.453; p = 0.006;
ηp
2 = 0.097) with higher daily consumption of cigarettes
(F(2,102) = 4.405; p = 0.015; ηp
2 = 0.080). Although the
groups did not differ in number of medical comorbidities,
the analysis by type of medical illness showed a higher
prevalence of HIV infection in the SUD group (χ2 = 5.816;
p = 0.050) and an increased incidence of triglycerides and
cholesterol in the SMI group compared with the other
two (χ2 = 7.467; p = 0.024). The CGI showed a worse clin-
ical state in both DD and SMI groups (F(2,102) = 25.097;
p = 0.0001; ηp
2 = 0.033) compared to the SUD group
(p= 0.0001). We did not find any differences in family psy-
chiatric history, family SUD history and daily number of
coffees or other beverages containing caffeine. No differ-
ences emerged between the DD and SMI groups in type
of psychiatric diagnosis, age of onset of mental illness and
years of illness duration.
Table 3 summarizes the data on substance consump-
tion for both DD and SUD groups. They did not differ
Table 2 Clinical data for the three groups of patients
Clinical data DD (N=35) SMI (N= 35) SUD (N=35)
Psychiatric Diagnosis (%= 100)
Schizophrenia 45.7% 80%
Bipolar Disorder 28.6% 14.3%
Major Depression Disorder 25.7% 5.7%
Age of psychiatric disorder onset 24.82 ± 7.47 yr 25.67 ± 8.07 yr
Mean duration of illness (yr) 12.27 ± 7.81 yr 14.09 ± 8.66 yr
Number of relatives with SUD 0.35 ± 0.69 0.06 ± 0.23 0.23 ± 0.59
Number of relatives with psychiatric disorder 0.65 ± 1.01 0.86 ± 0.87 0.49 ± 0.74
Number of suicidal attempts 1.60 ± 3.2 0.34 ± 0.68 0.34 ± 0.87
Number of medical comorbidities a 0.66 ± 1.05 0.57 ± 0.73 0.46 ± 0.78
Asthma/Allergy 11.4% 8.6% 2.9%
Triglycerides/Cholesterol 11.4% 25.7% 2.9%
Diabetes 2.9% 2.9% 2.9%
Obesity 2.9%
Hypertension 2.9% 8.6% 2.9%
HIV 5.7% 14.3%
Hepatitis B or C 5.7% 2.9% 5.7%
Others 14.3% 2.9% 5.7%
Daily number of medicationsa 3.86 ± 1.83 3.03 ± 1.20 0.69 ± 1.10
Typical antipsychotics 20.0% 17.1% 2.9%
Atypical antipsychotics 57.0%% 60.0% 5.7%
Antidepressants 28.6% 25.7% 11.4%
Mood stabilizers 25.0% 31.4% 8.6%
Anxiolytics 40% 22.9% 8.6%
Other medication 31.4% 25.7% 20%
Clinical Global Impression (CGI) 4.69 ± 0.96 4.50 ± 0.74 3.26 ± 1.01
Daily number of cigarettes 18.34 ± 12.41 10.43 ± 12.44 14.74 ± 8.08
Fagerström score 5.11 ± 2.52 2.89 ± 3.38 3.86 ± 2.48
No dependence 14.3% 54.3% 17.1%
Low dependence 8.6% 20.0%
Moderate dependence 45.7% 25.7% 51.4%
High dependence 31.4% 20% 11.4%
Daily Number of coffees (cups) 1.77 ± 1.73 1.17 ± 1.44 1.66 ± 1.43
Other daily beverages with caffeine 0.86 ± 1.00 0.71 ± 1.04 0.91 ± 1.26
DD, Dual Diagnosis; SMI, Severe Mental Illness; SUD, Substance Use Dependence.
a Percentage will not equal 100 as each participant may suffer from more than one medical illness or take more than one medication.
Benaiges et al. Health and Quality of Life Outcomes 2012, 10:106 Page 5 of 11
http://www.hqlo.com/content/10/1/106in number or type of intake, number of substances used,
type of substances used, months of abstinence, number
of relapses, age of onset of substance use or duration of
SUD disorder.
HRQOL comparisons
The results obtained in the 8 subscales and the two
composite scales of the SF-36 are shown in Table 4, as
well as the contrasts among groups. The analysesprovided main significant differences in most of the sub-
scales, except for Bodily Pain. The Health Transition
item and the composite scale MCS have also proved
significant.
The post-hoc analysis revealed a worse score for the
DD group in most of the subscales except in Role-
Physical and Role-Emotional compared to the SUD
group. The DD also obtained worse scoring in the
Health Transition item and in the MCS scale compared
Table 3 Substance Use data in Dual Diagnosis (DD) and
Substance Use Dependence (SUD) patients
Substance use data DD (N=35) SUD (N=35)
Type of intake
One substance 25.7% 20%
Two substances 25.9% 22.9%
Polydrug use 48.4% 57.1%
Number of substances used 2.80 ± 1.79 3.14 ± 1.53
Substance Abuse/Dependence a
Cocaine 100% 100%
Cannabis 54.3% 48.6%
Alcohol 71.4% 68.6%
Ecstasy 28.6% 25.7%
Hallucinogens 17.1% 14.3%
Opioids 22.9% 28.6%
Sedatives 5.7% 2.9%
Months of abstinence 13.41 ± 14.31 9.14 ± 5.07
Number of relapses 1.35 ± 2.52 0.54 ± 1.03
Age of intake onset (yr) 19.82 ± 7.32 20.00 ± 8.27
Mean duration of SUD (yr) 16.85 ± 7.32 15.60 ± 7.16
a Percentages will not equal 100 as each participant may take more than one
substance of abuse.
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the SMI group in most of the HRQOL domains except
for General Health and the Health Transition item. The
SUD and SMI groups only differed in Vitality, GeneralTable 4 Mean and standard deviation in the SF-36 and result
SF-36 DD (N=35) SMI (N= 35) SUD (N=35)
Subscales
Physical Functioning 86.40 ± 14.32 93.67 ± 9.23 96.00 ± 8. 20
Role- Physical 70.31 ± 39.36 92.64 ± 24.25 76.71 ± 40.58
Role-Emotional 46.87 ± 44.69 83.32 ± 34.09 68.55 ± 39.57
Social Functioning 60.56 ± 28.77 82.05 ± 26.98 80.71 ± 24.87
Mental Health 50.12 ± 19.27 62.47 ± 18.89 65.60 ± 17.22
General Health 50.46 ± 20.69 57.47 ± 21.07 73.74 ± 14.18
Bodily Pain 67.65 ± 25.24 77.32 ± 27.35 72.34 ± 25.95
Vitality 42.19 ± 16.36 51.91 ± 20.59 68.00 ± 16.54
Health Transition Item 63.28 ± 31.09 63.97 ± 24.76 92.14 ± 20.80
Composite Scales
PCS 50.31 ± 9.18 52.82 ±7.11 53.66 ± 7.80
MCS 34.61 ± 13.02 44.03 ± 12.49 45.42 ± 10.63
DD, Dual Diagnosis; MCS, Mental health Component Summary; PCS, Physical health
Dependence.
a We detail only the significant contrasts.
* p < 0.05; ** p < 0.001.Health and in the Health Transition item, without differ-
ences in the rest of the scales (see Table 4).
In view of significant group differences on certain clin-
ical variables, especially relevant in the DD group, we
carried out the analyses again introducing number of
daily medication, suicidal attempts and number of daily
cigarettes as covariates. The significance was maintained
for the scales of Physical Functioning (F(2,102) = 4.924;
p = 0.009; ηp
2 = 0.082), Role - Emotional (F(2,102) = 4.592;
p = 0.012; ηp
2 = 0.088), Social Functioning (F(2,102) = 3.012;
p = 0.050; ηp
2 = 0.060), Vitality (F(2,102) = 9.818; p = 0.0001;
ηp
2 = 0.171) and the Health Transition item (F(2,102) = 8.556;
p=0.0001; ηp
2 =0.153) with power sample values of≥0.760
in all cases. There were again no differences in the subscale
of Bodily Pain and the PCS scale. Previous main differences
in Role - Physical, Mental Health, General Health subscales
and in the MCS disappeared when the covariates were
introduced.
The contrast a posteriori only maintained the differ-
ences between the DD and SUD groups in Physical
Functioning (p = 0.031), Vitality (p = 0.0001) and in the
Health Transition item (p = 0.004), with a better score in
the SUD group. This group also presented a better score
in Vitality (p = 0.008) and in the Health Transition item
(p = 0.0001) with respect to the SMI group. The differ-
ences between the DD and SMI groups were maintained
for Physical Functioning (p = 0.015), Role - Emotional
(p = 0.016) and Social Functioning (p = 0.050), with lower
scores in the DD group.
The comparison of the group means with the Spanish
normative data [23] showed that, although all the groupss of the MANOVAs
MANOVA
F Effect size Power sample Contrasts a
7.06** 0.12 0.92 DD< SMI, SUD
3.50* 0.06 0.64 DD< SMI/DD= SUD
7.04** 0.12 0.92 DD< SMI/DD= SUD
6.58** 0.11 0.90 DD< SMI, SUD
6.47** 0.11 0.89 DD< SMI, SUD
13.60** 0.21 0.99 DD, SMI < SUD
1.12 0.02 0.24
17.76** 0.26 1.00 DD, SMI < SUD
14.03** 0.22 0.99 DD, SMI < SUD
1.54 0.03 0.32
7.82** 0.13 0.94 DD< SMI, SUD
Component Summary; SMI, Several Mental Illness; SUD, Substance Use
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in the DD group. The DD scores in the scales of Social
Functioning, Role - Emotional, Mental Health, General
Health and Vitality were below the norm. The SMI
group presented one standard deviation below the norm
only in the Vitality scale and the SUD group did not
present scores below the norm in any scale (see Figure 2).
Regarding the composite scales, the DD group was the
only one that was one standard deviation below the
norm in the MCS scale (see Figure 3).Factors contributing to HRQOL
The correlational analysis in the whole sample did not
provide any significant association between the score in
the PCS scales and the sociodemographic and clinical
variables. In contrast, the score in the MCS scale showed
negative associations with the number of suicidal
attempts (r =−0.268; p = 0.007), medication (r =−0.303;
p = 0.002) and daily number of coffees (r =−0.209;
p = 0.036). The correlational analysis taking into account
each group of patients only provided a significant associ-
ation in the DD group between the MCS scale and the
daily number of coffees (r =−0.497; p = 0.004). The sui-
cidal attempts and the medication did not reach signifi-
cance in any group.
These three variables were later introduced as inde-
pendent variables in a lineal regression analysis with the
whole sample and the MCS scale as a dependent vari-
able. The analysis of the general model was significant
(F = (3,102) = 6.536; p = 0.0001), explaining 14.2% of the
variance in the MCS scale. The results showed that daily
number of medications was related to the mental health
component of the HRQOL (see Table 5). When the
same analysis was done for each group, the general
model only maintained the significance in the DD group
(F(3,32) = 4.224; p = 0.010), explaining 21.8% of theFigure 2 Mean scores for the three groups of patients and the Spanis
Role – Physical; RE, Role – Emotional; SF, Social Functioning; MH, Mental He
Diagnosis; SMI, Severe Mental illness, SUD, Substance Use Dependence.variance, where the only significant variable was daily
consumption of coffee (see Table 5).Discussion
As we expected, the DD group presented worse HRQOL
scores in most of the scales compared to the other two
groups, especially in the mental health domain assessed
by the MCS scale. In contrast, the groups did not differ
in the scale of Bodily Pain or in Physical functioning
(PCS). In general, the SUD group had better scores in
most of the scales of the SF-36, with marked differences
with respect to the DD group, while the SMI group
obtained intermediate scores.
The introduction of the covariates suicidal attempts,
medication and daily consumption of cigarettes as vari-
ables that may be potentially associated to the HRQOL
and QOL [34-36] kept the worst HRQOL scores in the
DD group except for Mental Health, General Health and
MCS, where the three groups had similar scores. After
the adjustment, the SUD group showed a better feeling
of vitality and energy, and a better perception of the evo-
lution of the health state with respect to the previous
year (Health Transition item), compared to the SMI and
DD groups. The SUD group also showed a better per-
ception of the physical health state compared to the DD,
while there were no differences in the rest of the scales.
These data suggest that the SUD group shows a lower
functional disability, and this could be related to a better
community functioning, as suggested by the fact that in
this group there is a higher percentage of subjects who
are active workers.
Thus, suicide attempts, number of daily medication
and daily cigarette consumption appear to modulate the
differences between the DD and SUD groups regarding
HRQOL expression. These variables should be taken
into account in further research, since they may beh norms in the 8 scales of the SF-36. PF, Physical Functioning; RF,
alth; GH, General Health, BP, Bodily Pain; VT, Vitality.DD, Dual
Figure 3 Mean scores for the three groups of patients and the Spanish norms in the MCS and the PCS. MCS, Mental Health Component
Summary; PCS, Physical Component Summary. DD, Dual Diagnosis; SMI, Severe Mental Illness, SUD, Substance Use Dependence.
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http://www.hqlo.com/content/10/1/106determinant in DD scores on scales assessing the mental
domain of HRQOL. However, after the adjustment on
these clinical variables, the DD group continued showing
a lower degree of physical and emotional health, with
higher perceptions of limitations in daily social and
occupational life, as well as a higher feeling of tiredness
and exhaustion compared with the SMI group. This
result, in agreement with the work by Kalman et al. [17],
may highlight the moderating negative effect of sub-
stance use on the relationship between psychiatric
disorder and mental HRQOL in patients with DD.
This is also in line with the work by Kilbourne et al.
[16], who observed a negative association between sub-
stance consumption and the mental domain of the
HRQOL in bipolar patients, even after controlling for
the depressive and manic symptoms of the disorder. Our
results suggest a major detrimental effect on HRQOL in
people with a psychiatric disorder with comorbid SUD
than in those without comorbid SUD or other psychi-
atric disorders, despite clinical severity and other vari-
ables related to substance use, such as type of substance
used or time of abstinence. Although our results agree
with several previous studies [15-19], most of them only
compared DD and SUD patients, and they were lackingTable 5 Lineal regression for the MCS for the total sample an
MCS Adjusted
R2
IV ß s
TS (N =105) 0.142 Coffeeª −0
Medication b −0
DD (N= 35) 0.218
Suicidal Attempts
Coffeeª
Medication b
Suicidal Attempts
−0
−0
−0
−0
DD, Dual Diagnosis; IV, Independent Variables; MCS, Mental Health Component Sum
ª Daily number of coffees.
b Daily number of medications.the specific impact of the mental disorder related to
HRQOL in DD patients.
Regarding factors associated to HRQOL, the MCS
scale was negatively related with the number of suicidal
attempts, daily number of medication and daily number
of coffees. When there were more suicidal attempts,
more daily medication intake and/or a higher daily num-
ber of coffees, the score in the MCS scale was lower.
These variables were related to a worse state in the men-
tal domain of the HRQOL. However, the separate ana-
lysis by groups showed that the model was met only in
the case of DD patients, and that caffeine consumption
was the best predictive variable. Although this result
indicated that in DD patients the high number of coffees
taken is related to a higher affectation in the mental
domain of the HRQOL, coffee consumption in this
group was not higher than in the SMI or SUD groups.
Caffeine consumption, as well as other methylxanthines,
has long been associated with psychiatric illness, possibly
due to its beneficial impact on extrapyramidal side effects
of antipsychotic medication through dopaminergic agon-
ism in the nigrostratial pathways [37]. However, caffeine
consumption may have detrimental effects on DD patients
through dopaminergic agonists in other brain pathwaysd for the Dual Diagnosis group
tandardized p values Tolerance VIF
.179 0.059 0.975 1.025
.265 0.006 0.960 1.042
.188
.468
.171
.134
0.052
0.007
0.290
0.413
0.937
0.975
0.997
0.997
1.067
1.026
1.003
1.023
mary; TS, Total sample; VIF, Variance Inflation Factor.
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http://www.hqlo.com/content/10/1/106such as the mesolimbic and the mesocortical, resulting in
an increase of psychotic symptomatology. Since intraindi-
vidual variations have been described in the psychoactive
effects of caffeine in the general population [38], our
results point to the possibility that the DD population is
the most sensitive one to the effects of caffeine, even
under moderate doses compared to the other two groups.
Different hypotheses could explain this result. One
explanation could be that the DD group may present dif-
ferent genetic polymorphisms from the general popula-
tion, both in metabolic enzymes and in brain receptors to
the effects of caffeine. A more plausible explanation may
be that caffeine covaries with other risk factors associated
with the DD group: more suicidal attempts, higher daily
medication intake, and higher cigarette consumption.
Thus, caffeine intake has been associated with higher
cigarette consumption [39], and the consumption of both
substances has been in turn associated with a higher risk
of suicidal attempts in the psychiatric population [40,41]
and to a lower efficacy of the pharmacological treatment
[39,40]. All these factors, at the same time, have been dir-
ectly or indirectly associated with a worse QOL and
HRQOL [34-36,42,43].
Further research is needed in this area, exploring the
HRQOL state in the DD population, taking into account
the consumption of nicotine and caffeine in order to
explore their impact on HRQOL and with which risk
factors their effects may be associated. Likewise, study-
ing the QOL/HRQOL in DD women is of great interest,
since there is evidence of a worse state in the mental
domain in female substance users [21,44]. Thus, given
the differences in HRQOL state between sexes, it should
be noted that our results may be representative only of
male DD patients.Strengths and limitations of the study
In our study, we bring improvements over previous
research on this topic. The group comparisons to the
Spanish normative data have provided evidence of the
degree of impairment in the assessed domains of
HRQOL. We also bring new data on the major factors
associated with DD and lower mental HRQOL such as
suicidal attempts, cigarette smoking, daily caffeine intake
and number of prescribed medications. All these clinical
factors are rarely taken into account in previous studies.
Likewise, the control of abstinence time by urinalysis
and the calculations of power sample in all analyses are
important methodological factors preventing the influ-
ence of possible intermediate variables and their control
has provided strength to our results.
However, the limitations of the study should also be
noted. Although the cross-sectional study design allowed
us to ascertain the weight of each psychiatric condition inHRQOL of DD, it did not allow us to investigate causal
relationships between substance disorders, psychiatric
comorbidities and HRQOL. We failed to analyze the inde-
pendent effects of different types of substances on
HRQOL because a vast percentage of subjects in our sam-
ple were polyconsumers. Another important limitation is
that the study was based on clinically acquired and par-
tially retrospective self-reported data that may have been
subject to recall bias, including information about suicidal
acts and substance intake. The heterogeneity of the
psychiatric disorders included and the relatively small
sample size might have affected the representativeness of
the sample. Further, the inclusion of only males makes
difficult to interpret our findings as specific characteristics
of the subjects suffering from DD since the results cannot
be extrapolated to female gender. Noteworthy, we did not
include the information of the subjects who dropped out
the study or were excluded, so it is unknown whether the
results are subject to bias due to the exclusion of these
subjects. Finally, all subjects in our sample were contem-
plating treatment maybe affecting the generalisability of
the results to those subjects who were not considering
treatment.Conclusions
Overall, our findings show a worse state in the mental
domain of the HRQOL in the DD patients with respect
to the other two groups without comorbidity and to the
general population. Suicidal attempts, a higher intake of
daily medication and caffeine consumption appear as
factors associated to the impairment in the mental do-
main of the HRQOL, especially in the DD group. The
systematic assessment of the HRQOL in DD patients
should allow us to improve our knowledge of its asso-
ciated factors. It may also be a useful tool in the detec-
tion of areas of specific assistance to the goals of
treatment planning, thereby improving the effectiveness
of the intervention and the assessment of the results.
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